§ 22 §1728 — Prescription drug transparency report

1.
Hospital defined.
1-A.
Definitions.
As used in this section, unless the context otherwise indicates, the following terms have the following meanings.
2.
Report on participation in federal 340B drug program.
Beginning January 1, 2024, each hospital participating in the federal drug pricing program under Section 340B of the federal Public Health Service Act, 42 United States Code, Section 256b, referred to in this section as "the 340B program," shall provide an annual report to the Maine Health Data Organization. The Maine Health Data Organization shall post the report on its publicly accessible website. Each hospital shall report in a standardized format as agreed upon by the Maine Health Data Organization and the hospital, and include, at a minimum, the following information in the report consistent with the annual reporting of hospitals voluntarily participating in the good stewardship program of the American Hospital Association or its successor organization:
2-A.
Additional reporting by hospitals on participation in federal 340B drug program.
In addition to any report required pursuant to subsection 2, beginning July 1, 2026, each hospital participating in the 340B program shall provide an annual report to the Maine Health Data Organization. The Maine Health Data Organization shall post the report on its publicly accessible website. Each hospital shall report in a standardized format, as agreed upon by the Maine Health Data Organization and the hospital, and include, at a minimum, the following information in the report:
3.
Reporting.
The Maine Health Data Organization shall produce and post on its publicly accessible website a report that includes a summary of the aggregate information received from hospitals required to report under subsection 2 and subsection 2‑A. The Maine Health Data Organization shall submit the report required by this subsection to the Office of Affordable Health Care, as established in Title 5, section 3122, the Maine Prescription Drug Affordability Board, as established in Title 5, section 12004‑G, subsection 14‑I, and the joint standing committee of the Legislature having jurisdiction over health data reporting and prescription drug matters.

Legislative History

PL 2023, c. 276, §1 (NEW). PL 2025, c. 388, Pt. P, §§1-4 (AMD).